Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,978,745 shares, an increase of 4.4% from the February 15th total of 1,895,324 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily volume of 664,757 shares, the days-to-cover ratio is currently 3.0 days.

Shares of Hemispherx BioPharma (NYSEAMERICAN:HEB) opened at $0.47 on Friday. Hemispherx BioPharma has a one year low of $0.30 and a one year high of $0.84. The firm has a market cap of $14.21, a price-to-earnings ratio of -1.66 and a beta of -0.54.

A hedge fund recently raised its stake in Hemispherx BioPharma stock. Vanguard Group Inc. increased its holdings in Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 453,805 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,709 shares during the quarter. Vanguard Group Inc. owned approximately 1.56% of Hemispherx BioPharma worth $227,000 at the end of the most recent reporting period.

ILLEGAL ACTIVITY WARNING: “Short Interest in Hemispherx BioPharma, Inc (HEB) Increases By 4.4%” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/03/11/short-interest-in-hemispherx-biopharma-inc-heb-increases-by-4-4.html.

About Hemispherx BioPharma

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.